Evidence map›Paper›PMID 36825295›Full record

ArticleRSC advances2023

Morphological, cytotoxicity, and coagulation assessments of perlite as a new hemostatic biomaterial.

Esmaeil Biazar, Saeid Heidari Keshel, Vahid Niazi, Nader Vazifeh Shiran, Roxana Saljooghi, Mina Jarrahi, Ahmad Mehdipour Arbastan

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Esmaeil BiazarBiomaterials and Tissue Engineering Group, Department of Biomedical Engineering, Islamic Azad University Tonekabon Branch Tonekabon Iran e.biazar@toniau.ac.ir kia_esm@yahoo.com +981154271105 +981154271105.ORCID https://orcid.org/0000-0002-2367-2841
Saeid Heidari KeshelDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences Tehran Iran saeed.heidari@sbmu.ac.ir +989125870517 +989125870517.
Vahid NiaziStem Cell Research Center, Golestan University of Medical Science Gorgan Iran.
Nader Vazifeh ShiranDepartment of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University Tehran Iran.
Roxana SaljooghiBiomaterials and Tissue Engineering Group, Department of Biomedical Engineering, Islamic Azad University Tonekabon Branch Tonekabon Iran e.biazar@toniau.ac.ir kia_esm@yahoo.com +981154271105 +981154271105.
Mina JarrahiBiomaterials and Tissue Engineering Group, Department of Biomedical Engineering, Islamic Azad University Tonekabon Branch Tonekabon Iran e.biazar@toniau.ac.ir kia_esm@yahoo.com +981154271105 +981154271105.
Ahmad Mehdipour ArbastanSchool of Medicine, Faculty of Medical Sciences, Islamic Azad University Tonekabon Branch Tonekabon Iran.
Islamic Azad University Tonekabon · IRGolestan University · IRShahid Beheshti University of Medical Sciences · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemorrhage control is vital for clinical outcomes after surgical treatment and pre-hospital trauma injuries. Numerous biomaterials have been investigated to control surgical and traumatic bleeding. In this study, for the first time, perlite was introduced as an aluminosilicate biomaterial and compared with other ceramics such as kaolin and bentonite in terms of morphology, cytotoxicity, mutagenicity, and hemostatic evaluations. Cellular studies showed that perlite has excellent viability, good cell adhesion, and high anti-mutagenicity. Coagulation results demonstrated that the shortest clotting time (140 seconds with a concentration of 50 mg mL

Identifiers

PMID36825295
PMCPMC9941756
OpenAlexW4321461587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.